Docking-Based Virtual Screening Using PyRx Tool: Autophagy Target Vps34 as a Case Study

Abstract Virtual screening (VS) is a computational approach used to screen a large number of database molecules to identify leads. It decreases both the time and resources required to test the whole database experimentally, by selecting only the most promising ones. Docking-based virtual screening (DBVS) methods explore the behavior of small molecules in the binding pocket of targets, to select the best interacting molecules for testing experimentally. Several docking programs/software have been developed to perform DBVS of large databases. This chapter describes the use of one such open-access tool PyRx 0.8 ( https://pyrx.sourceforge.io/ ; https://sourceforge.net/projects/pyrx/ ), which is user-friendly and can run on many operating systems. This tool combines several open-source software, including AutoDock, AutoDock Vina, and Open Babel to carry out DBVS seamlessly. We demonstrate in a step-by-step manner the use of the PyRx tool to perform DBVS of database compounds for autophagy target Vps34 (vacuolar protein sorting 34), to identify potential molecules for testing in the lab. Overall, this chapter provides an easy understanding and systematic protocol to use the PyRx tool for carrying out DBVS, with a case study.

[1]  K. Lam,et al.  Combinatorial chemistry in drug discovery. , 2017, Current opinion in chemical biology.

[2]  Gideon Adamu Shallangwa,et al.  Quantum modelling and molecular docking evaluation of some selected quinoline derivatives as anti-tubercular agents , 2020, Heliyon.

[3]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[4]  Sree Karani Kondapuram,et al.  Targeting autophagy with small molecules for cancer therapy , 2019, Journal of Cancer Metastasis and Treatment.

[5]  R. Grundy,et al.  RHPS4 G-Quadruplex Ligand Induces Anti-Proliferative Effects in Brain Tumor Cells , 2014, PloS one.

[6]  Stefano Forli,et al.  Charting a Path to Success in Virtual Screening , 2015, Molecules.

[7]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[8]  J. Gamieldien,et al.  Practical Considerations in Virtual Screening and Molecular Docking , 2015, Emerging Trends in Computational Biology, Bioinformatics, and Systems Biology.

[9]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[10]  G. Berchem,et al.  Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy , 2020, Science Advances.

[11]  Ruth Huey,et al.  Computational protein–ligand docking and virtual drug screening with the AutoDock suite , 2016, Nature Protocols.

[12]  B. Epe,et al.  The repair of oxidized purines in the DNA of human lymphocytes requires an activation involving NF-YA-mediated upregulation of OGG1. , 2015, DNA repair.

[13]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[14]  A. Pedretti,et al.  Homology Modeling of Leishmanolysin (gp63) from Leishmania panamensis and Molecular Docking of Flavonoids , 2020, ACS omega.

[15]  Mohane Selvaraj Coumar,et al.  An Overview of Computational Methods, Tools, Servers, and Databases for Drug Repurposing , 2019, In Silico Drug Design.

[16]  S. Nicholls,et al.  Anacetrapib as a potential cardioprotective strategy , 2017, Drug design, development and therapy.

[17]  Richard C. Mohs,et al.  Drug discovery and development: Role of basic biological research , 2017, Alzheimer's & dementia.

[18]  Leonardo L. G. Ferreira,et al.  Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.

[19]  T. Efferth,et al.  A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening , 2018, Journal of advanced research.

[20]  Rie Kondo,et al.  Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis , 2011, BMC Cancer.

[21]  Noel M. O'Boyle,et al.  De novo design of molecular wires with optimal properties for solar energy conversion , 2011, Journal of Cheminformatics.

[22]  Z. Qian,et al.  VPS34 stimulation of p62 phosphorylation for cancer progression , 2017, Oncogene.

[23]  M. Elisaf,et al.  Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy. , 2017, Journal of thoracic disease.

[24]  I. Novak,et al.  Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy , 2018, Oxidative medicine and cellular longevity.

[25]  Smrita Singh,et al.  In silico identification of potential drug compound against Peroxisome proliferator-activated receptor-gamma by virtual screening and toxicity studies for the treatment of Diabetic Nephropathy , 2018, Journal of biomolecular structure & dynamics.

[26]  V. Yadav,et al.  Designing quorum sensing inhibitors of Pseudomonas aeruginosa utilizing FabI: an enzymic drug target from fatty acid synthesis pathway , 2019, 3 Biotech.

[27]  Arthur J Olson,et al.  Small-molecule library screening by docking with PyRx. , 2015, Methods in molecular biology.

[28]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[29]  J. Hood,et al.  A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. , 2018, Osteoarthritis and cartilage.

[30]  Glaucius Oliva,et al.  Modern drug discovery technologies: opportunities and challenges in lead discovery. , 2011, Combinatorial chemistry & high throughput screening.

[31]  V. Shukla,et al.  An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2 , 2020, Journal of Ayurveda and Integrative Medicine.

[32]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[33]  C. Telleria,et al.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression , 2011, BMC Cancer.

[34]  P. Codogno,et al.  Autophagy: A Druggable Process. , 2017, Annual review of pharmacology and toxicology.

[35]  G. Cohen,et al.  S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth , 2018, Oncotarget.

[36]  Tingjun Hou,et al.  Combined strategies in structure-based virtual screening. , 2020, Physical chemistry chemical physics : PCCP.

[37]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[38]  A. Antoccia,et al.  The G-quadruplex-stabilising agent RHPS4 induces telomeric dysfunction and enhances radiosensitivity in glioblastoma cells. , 2015, DNA repair.

[39]  Wei Tian,et al.  CASTp 3.0: computed atlas of surface topography of proteins , 2018, Nucleic Acids Res..

[40]  Mary G. Lin,et al.  Vps34 Kinase Domain Dynamics Regulate the Autophagic PI 3-Kinase Complex. , 2017, Molecular cell.

[41]  Shankargouda Patil,et al.  Autophagy in health and disease: A comprehensive review. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[43]  Dik-Lung Ma,et al.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics , 2013, Evidence-based complementary and alternative medicine : eCAM.